Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 231-233, 2008; 10.1373/clinchem.2007.099705
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koenig, W.
Right arrow Articles by Meisinger, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koenig, W.
Right arrow Articles by Meisinger, C.
(Clinical Chemistry. 2008;54:231-233.)
© 2008 American Association for Clinical Chemistry, Inc.

Editorials

Uric Acid, Type 2 Diabetes, and Cardiovascular Diseases: Fueling the Common Soil Hypothesis?

Wolfgang Koenig1,a and Christa Meisinger2,3

1 Department of Internal Medicine II–Cardiology, University of Ulm Medical Center, Ulm, Germany, 2 Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Institute of Epidemiology, Germany, 3 MONICA/KORA Myocardial Infarction Registry, Central Hospital, Augsburg, Germany

aAddress correspondence to this author at, Department of Internal Medicine II–Cardiology, University of Ulm Medical Center, Robert-Koch Str. 8, D-89081 Ulm, Germany, Fax ++49-731-500-45021, E-mail wolfgang.koenig@uniklinik-ulm.de

The first 20% of the full text of this article appears below.

Uric acid is the final oxidation product of purine catabolism. Excess serum accumulation can lead to various diseases, and most notably uric acid is causally involved in the pathogenesis of gouty arthritis. Also, for more than 50 years, increased serum concentrations of uric acid have been implicated in cardiovascular disease. Uric acid’s contribution to atherosclerotic vascular disease, however, is still somewhat controversial. Various mechanisms have been suggested through which uric acid may be implicated in the atherosclerotic process and its clinical complications. Uric acid can act as a prooxidant, particularly at increased concentrations, and may thus be a marker of oxidative stress (1)(2), but it may also have a therapeutic role as an antioxidant (3)(4). Plasma uric acid concentrations correlate with longevity in primates and other mammals (5), a characteristic that is presumably a function of urate’s antioxidant properties. Thus, it is unclear whether increased concentrations of uric acid in diseases associated with oxidative stress, such as atherosclerotic coronary heart disease (CHD), stroke, and peripheral arterial occlusive disease, are a protective response or a primary cause. Some researchers have proposed that hyperuricemia-induced oxidative stress represents a cause of the metabolic syndrome (6). Hyperuricemia has been found to be associated with obesity and insulin resistance, and consequently with type 2 diabetes (7)(8). Further potentially important biological effects of uric acid . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.